Modification of cardiac subcellular remodeling due to pressure overload by captopril and losartan.

In view of the activation of renin-angiotensin system under conditions associated with pressure overload on the heart, we examined the effects of captopril, an angiotensin converting enzyme inhibitor, and losartan, an angiotensin II receptor antagonist, on cardiac function, myofibrillar ATPase and sarcoplasmic reticular (SR) Ca2+-pump (SERCA2) activities, as well as myosin and SERCA2 gene expression in hypertrophied hearts. Cardiac hypertrophy was induced in rats treated with or without captopril or losartan by banding the abdominal aorta for 8 weeks; sham operated animals served as control. Decrease in left ventricular developed pressure, +dP/dt and -dP/dt as well as increase in left ventricular end diastolic pressure and increased muscle mass due to pressure overload were prevented by captopril or losartan. Treatment of animals with captopril or losartan also attenuated the pressure overload-induced depression in myofibrillar Ca2+-stimulated ATPase, myosin ATPase, SR Ca2+-uptake and SR Ca2+-release activities. An increase in beta-myosin heavy chain mRNA and a decrease in alpha-myosin heavy chain mRNA as well as depressed SERCA2 protein and SERCA2 mRNA levels were prevented by captopril or losartan. These results suggest that both captopril and losartan improve myocardial function in cardiac hypertrophy by preventing changes in gene expression and subsequent subcellular remodeling due to pressure overload.

[1]  N. Dhalla,et al.  Modification of ischemia-reperfusion-induced changes in cardiac sarcoplasmic reticulum by preconditioning. , 1998, The American journal of physiology.

[2]  Y. Pinto,et al.  Effects of quinapril, losartan and hydralazine on cardiac hypertrophy and β‐adrenergic neuroeffector mechanisms in transgenic (mREN2)27 rats , 1998, British journal of pharmacology.

[3]  M. Hefti,et al.  Modulation of contractility in human cardiac hypertrophy by myosin essential light chain isoforms. , 1998, Cardiovascular research.

[4]  Y. Pinto,et al.  Angiotensin receptor antagonism and angiotensin converting enzyme inhibition improve diastolic dysfunction and Ca2+‐ATPase expression in the sarcoplasmic reticulum in hypertensive cardiomyopathy , 1997, Journal of hypertension.

[5]  Y. Kihara,et al.  Early changes in the functions of cardiac sarcoplasmic reticulum in volume-overloaded cardiac hypertrophy in rats. , 1997, Journal of molecular and cellular cardiology.

[6]  D. Lu,et al.  Chronic control of high blood pressure in the spontaneously hypertensive rat by delivery of angiotensin type 1 receptor antisense. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[7]  N. Dhalla,et al.  Modification of sarcoplasmic reticulum gene expression in pressure overload cardiac hypertrophy by etomoxir , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[8]  I. Dixon,et al.  Altered mRNA abundance of calcium transport genes in cardiac myocytes induced by angiotensin II. , 1996, Journal of molecular and cellular cardiology.

[9]  I. Dixon,et al.  Regression of hypertrophy after myocardial infarction is produced by the chronic blockade of angiotensin type 1 receptor in rats. , 1996, Journal of molecular and cellular cardiology.

[10]  M. Böhm,et al.  Dose-dependent dissociation of ACE-inhibitor effects on blood pressure, cardiac hypertrophy, and beta-adrenergic signal transduction. , 1995, Circulation.

[11]  J. Cruickshank,et al.  Reversibility of left ventricular hypertrophy by differing types of antihypertensive therapy. , 1992, Journal of human hypertension.

[12]  N. Dhalla,et al.  Modification of subcellular organelles in pressure‐overloaded heart by etomoxir, a carnitine palmitoyltransferase I inhibitor , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[13]  N. Dhalla,et al.  Nitrendipine binding in congestive heart failure due to myocardial infarction. , 1990, Circulation research.

[14]  N. Dhalla,et al.  Pathophysiological aspects of myocardial hypertrophy. , 1987, The Canadian journal of cardiology.

[15]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[16]  N. Dhalla,et al.  Sarcoplasmic reticular and mitochondrial calcium transport in cardiac hypertrophy. , 1985, The Canadian journal of cardiology.

[17]  N. Dhalla,et al.  Alterations in sarcolemmal Na+-Ca2+ exchange and ATP-dependent Ca2+-binding in hypertrophied heart. , 1985, The Canadian journal of cardiology.

[18]  G. Pierce,et al.  Mechanisms of the defect in cardiac myofibrillar function during diabetes. , 1985, The American journal of physiology.

[19]  N. Dhalla,et al.  Defective sarcoplasmic reticular calcium transport in diabetic cardiomyopathy. , 1983, The American journal of physiology.

[20]  Alpert Nr,et al.  Heat, mechanics, and myosin ATPase in normal and hypertrophied heart muscle. , 1982 .

[21]  B. Swynghedauw,et al.  Myosin Isoenzymic Changes in Several Models of Rat Cardiac Hypertrophy , 1981, Circulation research.

[22]  C. Limas,et al.  Enhanced calcium transport by sarcoplasmic reticulum in mild cardiac hypertrophy. , 1980, Journal of molecular and cellular cardiology.

[23]  W. Parmley,et al.  The Cardiac Hypertrophy Process , 1979, Circulation research.

[24]  J. Lamers,et al.  Defective calcium pump in the sarcoplasmic reticulum of the hypertrophied rabbit heart. , 1979, Life sciences.

[25]  J. Suko,et al.  Intracellular calcium and myocardial contractility. V. Calcium uptake of sarcoplasmic reticulum fractions in hypertrophied and failing rabbit hearts. , 1974, Journal of molecular and cellular cardiology.

[26]  W. G. Wood,et al.  Mitochondria and sarcoplasmic reticulum function in cardiac hypertrophy and failure. , 1973, The American journal of physiology.

[27]  M. Ruzicka,et al.  Relevance of blockade of cardiac and circulatory angiotensin-converting enzyme for the prevention of volume overload-induced cardiac hypertrophy. , 1995, Circulation.

[28]  D. Ganten,et al.  Converting enzyme inhibition specifically prevents the development and induces regression of cardiac hypertrophy in rats. , 1989, Clinical and experimental hypertension. Part A, Theory and practice.

[29]  L S Hibbard,et al.  Cerebral glucose use measured with [14C]glucose labeled in the 1, 2, or 6 position. , 1985, The American journal of physiology.

[30]  F. Dunn,et al.  Enalapril improves systemic and renal hemodynamics and allows regression of left ventricular mass in essential hypertension. , 1984, The American journal of cardiology.